The CCB is a Medical Research Institute which carries out a world-class program of innovative research, making breakthrough discoveries in the fundamental causes of cancer, and translating these discoveries into new ways to prevent and treat this group of diseases.
The CCB is an alliance between SA Pathology and the University of South Australia and boasts the largest concentration of cancer research in South Australia, currently hosting 22 full-time research group leaders and their teams.
CCB laboratories carry out research in leukaemia, breast cancer, prostate cancer, skin cancer, brain cancer and colon cancer, focussing in the specialised areas of gene regulation, molecular signalling, translational oncology and cancer genomics. In addition to these laboratories, our ACRF cancer Genomics Facility is providing access to state-of-the-art genomics research equipment, computing technology and bioinformatics expertise to Adelaide BioMed Precinct and the wider research community.
Translation of new discoveries into clinical practice is strengthened by the co-localisation of the laboratories within a single Institute, as well as its proximity and close collaboration with the Royal Adelaide Hospital, the University of South Australia, the University of Adelaide and SAHMRI.
The CCB also has alliances with leading pharmaceutical companies to rapidly exploit new discoveries. The Institute aims to be a hub of internationally recognized cancer research excellence, achieving tangible outcomes for cancer patients.
The CCB is a member of the Association of Australian Medical Research Institutes (AAMRI).
